This study attempted to summarise several of the most current pieces of evidence concerning clinical trials involving biologic medicines [i.e. omalizumab (OMA)] and were linked to allergen-specific immunotherapy as a supplement (AIT). According to the current research, OMA may be a helpful supplement to AIT for respiratory allergy or food desensitisation, particularly during the escalation or build-up phases, when side effects are more likely. The hopeful data regarding hymenoptera venom allergy is yet confined to case reports, and there is no organised clinical study available.
Studies using OMA in conjunction with AIT have yielded encouraging results during the last decade. Today, large randomised, double-blind, placebo-controlled trials are required to better select patients who might benefit from the addition of OMA (or other biologic medicines) to AIT, as well as appropriate dosage regimens, therapy duration, and, lastly, proper pharmacoeconomic assessment.